WILMINGTON, MA--(Marketwire -11/10/11)- Implant Sciences Corporation (OTCQB: IMSC.PK - News) (Pinksheets: IMSC.PK - News), a high technology supplier of systems and sensors for homeland security markets, today announced sales of its Quantum Sniffer™ QS-H150 handheld explosives trace detectors to a new customer in Uzbekistan. The sale was made through Implant Sciences' new regional distributor PS, LLC. The portable, high performance, low weight devices will be deployed for airport security in the Central Asian nation. This is Implant Sciences' first sale in Uzbekistan.
Implant Sciences recently signed a distribution agreement with PS, LLC, a US-based company with a representative office in Tashkent, Uzbekistan. PS's customers include commercial organizations and governmental agencies. The distributor is a major provider of security systems and detection equipment for Uzbekistan Airways and all major airports in Uzbekistan. PS provides a full range of services for security applications including consulting, project development, installations, equipment launch, technical support, maintenance and staff training.
"In both air cargo and in airport passenger security, the QS-H150's functionality is very well suited for flexible and continuous use. Our devices are gaining an increasing presence in the critical airport security market globally," stated Glenn D. Bolduc, President and CEO of Implant Sciences.
About the Quantum Sniffer™ QS-H150
The QS-H150 is a handheld explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.
About the Quantum Sniffer™ QS-B220
The QS-B220, introduced in May 2011, is a benchtop explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, plus narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.
About Implant Sciences
Implant Sciences develops, manufactures, and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed innovative proprietary technologies used in its explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences products have been deployed in a wide range of security environments including airports, subways, railways, cargo facilities, nuclear power plants, police departments, military units, government buildings, and financial institutions. The QS-H150 and QS-B220 are Department of Homeland Security (DHS) Qualified Anti-Terrorism Technologies under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.